JOP20230243A1 - طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد - Google Patents

طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد

Info

Publication number
JOP20230243A1
JOP20230243A1 JOJO/P/2023/0243A JOP20230243A JOP20230243A1 JO P20230243 A1 JOP20230243 A1 JO P20230243A1 JO P20230243 A JOP20230243 A JO P20230243A JO P20230243 A1 JOP20230243 A1 JO P20230243A1
Authority
JO
Jordan
Prior art keywords
methods
treating cancer
antigen
formulations
agent
Prior art date
Application number
JOJO/P/2023/0243A
Other languages
Arabic (ar)
English (en)
Inventor
Krishnamachari Yogita
Keith Chartash Elliot
Gheyas Ferdous
Naga Ratna Pavan Kumar Vaddady Venkata
De Miranda Silva Carolina
Jain Lokesh
Lala Mallika
Original Assignee
Merck Sharp And Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp And Dohme Llc filed Critical Merck Sharp And Dohme Llc
Publication of JOP20230243A1 publication Critical patent/JOP20230243A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JOJO/P/2023/0243A 2021-04-08 2023-10-08 طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد JOP20230243A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163172299P 2021-04-08 2021-04-08
PCT/US2022/023250 WO2022216580A1 (en) 2021-04-08 2022-04-04 Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies

Publications (1)

Publication Number Publication Date
JOP20230243A1 true JOP20230243A1 (ar) 2023-10-08

Family

ID=83546458

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2023/0243A JOP20230243A1 (ar) 2021-04-08 2023-10-08 طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد

Country Status (21)

Country Link
US (1) US20250074983A1 (enExample)
EP (1) EP4320163A4 (enExample)
JP (1) JP2024513247A (enExample)
KR (1) KR20230170029A (enExample)
CN (1) CN117279952A (enExample)
AR (1) AR125296A1 (enExample)
AU (1) AU2022254960A1 (enExample)
BR (1) BR112023020867A2 (enExample)
CA (1) CA3214617A1 (enExample)
CL (1) CL2023002976A1 (enExample)
CO (1) CO2023013273A2 (enExample)
CR (1) CR20230473A (enExample)
DO (1) DOP2023000216A (enExample)
EC (1) ECSP23076276A (enExample)
GE (1) GEAP202416385A (enExample)
IL (1) IL307430A (enExample)
JO (1) JOP20230243A1 (enExample)
MX (1) MX2023011857A (enExample)
PE (1) PE20240051A1 (enExample)
TW (1) TW202305009A (enExample)
WO (1) WO2022216580A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102650991B1 (ko) 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물
WO2025140467A1 (zh) * 2023-12-29 2025-07-03 上海复宏汉霖生物技术股份有限公司 稳定的高浓度抗pd-1抗体药物制剂

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
NZ542873A (en) 2003-03-05 2008-07-31 Halozyme Inc Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018223182A1 (en) * 2017-06-05 2018-12-13 The Council Of The Queensland Institute Of Medical Research A combination of, or a bispecific binding molecule to, an immune checkpoint molecule antagonist and a rank-l (nf- kb ligand) antagonist for cancer therapy or prophylaxis and uses therefor.
JP2021513540A (ja) * 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体及び抗ｃｔｌａ４抗体によるがんの処置方法
MX2020009824A (es) 2018-07-25 2021-01-15 Alteogen Inc Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
EP3876978A4 (en) * 2018-11-07 2022-09-28 Merck Sharp & Dohme Corp. STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF
KR102650991B1 (ko) * 2019-03-25 2024-03-27 (주)알테오젠 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물

Also Published As

Publication number Publication date
TW202305009A (zh) 2023-02-01
KR20230170029A (ko) 2023-12-18
JP2024513247A (ja) 2024-03-22
WO2022216580A1 (en) 2022-10-13
ECSP23076276A (es) 2023-11-30
CL2023002976A1 (es) 2024-06-28
CO2023013273A2 (es) 2023-10-30
AR125296A1 (es) 2023-07-05
DOP2023000216A (es) 2023-11-30
AU2022254960A9 (en) 2023-11-30
AU2022254960A1 (en) 2023-11-23
EP4320163A4 (en) 2025-03-05
CR20230473A (es) 2023-11-30
MX2023011857A (es) 2023-10-19
CA3214617A1 (en) 2022-10-13
IL307430A (en) 2023-12-01
GEAP202416385A (en) 2024-02-26
US20250074983A1 (en) 2025-03-06
BR112023020867A2 (pt) 2023-12-12
PE20240051A1 (es) 2024-01-09
EP4320163A1 (en) 2024-02-14
CN117279952A (zh) 2023-12-22

Similar Documents

Publication Publication Date Title
MX2022009044A (es) Conjugado de farmaco de derivado de eribulin, metodo de preparacion y aplicacion del mismo en medicina.
JOP20230243A1 (ar) طرق لعلاج السرطان بواسطة إعطاء أجسام مضادة موجّهة ضد pd1 تحت الجلد
MX2023013227A (es) Regimen de dosis para terapia combinada dirigida a dll3 y pd-1.
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
GEAP202516662A (en) Anti-nectin-4 antibody, conjugate including same, and application thereof
MX2024015058A (es) Terapia combinada de agente activo anti proteína de muerte programada 1 (pd-1), agente activo anti dominio 3 de inmunoglobulina y mucina de linfocitos t (tim-3) y agente activo anti gen 3 de activación de linfocitos (lag-3) para tratar el cáncer
Yang et al. A Phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma
MX2024006799A (es) Metodos para el tratamiento de cáncer con prame positivo.
MX2025005378A (es) Metodos para el tratamiento de enfermedades cardiovasculares
CL2025003511A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1.
CR20220127A (es) Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1
MX2024007749A (es) Formulaciones clinicas de anticuerpos anti-tigit.
MX2024009972A (es) Terapias combinadas para el tratamiento del cancer que comprenden un conjugado de farmaco anticuerpo b7-h4.
MX2023013614A (es) Uso de conjugado farmaco-anticuerpo en combinacion con inhibidor de puntos de control inmunitario en el tratamiento del cancer urotelial.
JOP20250015A1 (ar) تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها
MX2024012319A (es) Conjugado anticuerpo-fármaco que comprende anticuerpo contra transductor de señal de calcio asociado a tumor 2 (trop2) humano y uso de este
JOP20240049A1 (ar) سوتوراسيب وجسم مضاد لـ egfr لعلاج سرطان يشمل طفرة kras g12c
MX2022013031A (es) Regimen de dosificacion para el tratamiento de una enfermedad modulada por csf-1r.
Stotts et al. A psoriasiform drug eruption secondary to nivolumab for hepatocellular carcinoma: a case report
AR124527A1 (es) Métodos de tratamiento de tumores
AR130745A1 (es) Composiciones y métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1
WO2024187137A3 (en) Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
AR133816A1 (es) Conjugado anticuerpo-fármaco
MX2024009564A (es) Composicion farmaceutica para tratamiento de cancer que comprende proteina de fusion que incluye il-12 y anticuerpo anti-fap, y uso de la misma.
AR117120A1 (es) Terapia de combinación que incluye un inhibidor de krasg¹²c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres